Extended dosing intervals in DME maintained through 2 years with aflibercept 8 mg
Click Here to Manage Email Alerts
Key takeaways:
- Through 2 years, 89% of patients maintained dosing intervals of at least 12 weeks.
- Aflibercept 8 mg had a safety profile consistent with previous studies of Eylea.
Patients who received aflibercept 8 mg for diabetic macular edema maintained dosing intervals through 2 years, according to a press release from Regeneron.
The double-masked, active-controlled pivotal PHOTON trial evaluated the noninferiority of aflibercept 8 mg with dosing regimens of 12 weeks (328 patients) and 16 weeks (163 patients) after three initial monthly doses compared with Eylea (aflibercept 2 mg) with a dosing regimen of 8 weeks (167 patients) after five initial monthly doses.
Image: Adobe Stock
Through 2 years, 89% of patients maintained dosing intervals of at least 12 weeks, 83% maintained dosing intervals of at least 16 weeks, and 43% met the criteria for dosing intervals of at least 20 weeks, according to the release.
In addition, visual gains with aflibercept 8 mg were consistent with the first year of the trial.
The safety of aflibercept 8 mg was similar to Eylea through 2 years and consistent with the known safety profile from previous clinical trials for DME.
“The 2-year PHOTON results for aflibercept 8 mg in patients with diabetic macular edema are extremely compelling,” trial investigator Jeffrey Heier, MD, said in the release, “To be able to rapidly achieve extended dosing intervals without any sacrifice of vision gains over 2 years is a tremendous benefit in the treatment of diabetic macular edema.”
Read more about
Click Here to Manage Email Alerts